Protalix BioTherapeutics Q4 GAAP EPS $(0.07) Misses $(0.03) Estimate, Sales $10.49M Beat $5.80M Estimate
Author: Benzinga Newsdesk | March 14, 2024 06:56am
Protalix BioTherapeutics (AMEX:
PLX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $10.49 million which beat the analyst consensus estimate of $5.80 million by 80.79 percent. This is a 21.69 percent increase over sales of $8.62 million the same period last year.
Posted In: PLX